Advertisement

Optimal Strategies in Medical Management of Frontal Sinusitis

  • Kristine A. Smith
  • Jeremiah A. Alt
  • Richard R. Orlandi
Chapter

Abstract

Chronic rhinosinusitis (CRS) is an inflammatory condition of the sinonasal passages. Medical therapy is an essential component in the management of CRS and is often necessary for successful long-term symptom control and the control of disease recurrence. The primary goal of medical therapy is to reduce sinonasal mucosal inflammation. The frontal sinus is the most complex sinus to manage in patients with CRS, in part due to its challenging anatomy and difficulty of delivering topical anti-inflammatory medications through the frontal recess due the presence of variable and complex frontal cells, which may partially or completely obstruct the frontal recess. While endoscopic sinus surgery (ESS) may improve the delivery of medication to the frontal recess, stenosis and disease recurrence are common, and prolonged medical therapy is often required. A variety of medical therapies are currently available for the management of CRS, and many innovative therapies are currently being investigated. Understanding the different types of therapies available, as well as the evidence and role for these therapies, is essential to aid clinicians in managing frontal sinusitis. The objective of this chapter is to review the available medical therapies, the most up-to-date evidence for these therapies, and their role in the management of frontal sinusitis.

Keywords

Chronic rhinosinusitis Sinusitis Frontal Medical therapy Nasal polyposis 

References

  1. 1.
    Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1–12.CrossRefGoogle Scholar
  2. 2.
    Rudmik L, Soler ZM. Medical therapies for adult chronic sinusitis: a systematic review. JAMA. 2015;314(9):926–39.CrossRefGoogle Scholar
  3. 3.
    Lee WT, Kuhn FA, Citardi MJ. 3D computed tomographic analysis of frontal recess anatomy in patients without frontal sinusitis. Otolaryngol Head Neck Surg. 2004;131(3):164–73.CrossRefGoogle Scholar
  4. 4.
    Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Alt JA, Baroody FM, et al. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(Suppl 1):S22–209.PubMedGoogle Scholar
  5. 5.
    DeConde AS, Smith TL. Outcomes after frontal sinus surgery: an evidence-based review. Otolaryngol Clin N Am. 2016;49(4):1019–33.CrossRefGoogle Scholar
  6. 6.
    Kalish L, Snidvongs K, Sivasubramaniam R, Cope D, Harvey RJ. Topical steroids for nasal polyps. Cochrane Database Syst Rev. 2012;12:CD006549.PubMedGoogle Scholar
  7. 7.
    Snidvongs K, Kalish L, Sacks R, Craig JC, Harvey RJ. Topical steroid for chronic rhinosinusitis without polyps. Cochrane Database Syst Rev. 2011(8):CD009274.Google Scholar
  8. 8.
    Kerr EA, Hayward RA. Patient-centered performance management: enhancing value for patients and health care systems. JAMA. 2013;310(2):137–8.CrossRefGoogle Scholar
  9. 9.
    Chong LY, Head K, Hopkins C, Philpott C, Glew S, Scadding G, et al. Saline irrigation for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011995.PubMedGoogle Scholar
  10. 10.
    Chong LY, Head K, Hopkins C, Philpott C, Schilder AG, Burton MJ. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011996.PubMedGoogle Scholar
  11. 11.
    Thomas WW 3rd, Harvey RJ, Rudmik L, Hwang PH, Schlosser RJ. Distribution of topical agents to the paranasal sinuses: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2013;3(9):691–703.CrossRefGoogle Scholar
  12. 12.
    Rudmik L, Soler ZM, Hopkins C, Schlosser RJ, Peters A, White AA, et al. Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Int Forum Allergy Rhinol. 2016;6(6):557–67.CrossRefGoogle Scholar
  13. 13.
    Smith KA, French G, Mechor B, Rudmik L. Safety of long-term high-volume sinonasal budesonide irrigations for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(3):228–32.CrossRefGoogle Scholar
  14. 14.
    Harvey RJ, Snidvongs K, Kalish LH, Oakley GM, Sacks R. Corticosteroid nasal irrigations are more effective than simple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery. Int Forum Allergy Rhinol. 2018;8(4):461–70.CrossRefGoogle Scholar
  15. 15.
    Smith KA, Rudmik L. Delivery of topical therapies. In: Woodworth BA, Poetker DM, Reh DD, editors. Advances in oto-rhino-laryngology – Rhinosinusitis with nasal polyposis. Basel/New York: Karger; 2016.Google Scholar
  16. 16.
    Fokkens WJ, Ebbens F, van Drunen CM. Fungus: a role in pathophysiology of chronic rhinosinusitis, disease modifier, a treatment target, or no role at all? Immunol Allergy Clin N Am. 2009;29(4):677–88.CrossRefGoogle Scholar
  17. 17.
    Schwartz JS, Tajudeen BA, Cohen NA. Medical management of chronic rhinosinusitis – an update. Expert Rev Clin Pharmacol. 2016;9(5):695–704.CrossRefGoogle Scholar
  18. 18.
    Lee JT, Chiu AG. Topical anti-infective sinonasal irrigations: update and literature review. Am J Rhinol Allergy. 2014;28(1):29–38.CrossRefGoogle Scholar
  19. 19.
    Barham HP, Ramakrishnan VR, Knisely A, Do TQ, Chan LS, Gunaratne DA, et al. Frontal sinus surgery and sinus distribution of nasal irrigation. Int Forum Allergy Rhinol. 2016;6(3):238–42.CrossRefGoogle Scholar
  20. 20.
    Singhal D, Weitzel EK, Lin E, Feldt B, Kriete B, McMains KC, et al. Effect of head position and surgical dissection on sinus irrigant penetration in cadavers. Laryngoscope. 2010;120(12):2528–31.CrossRefGoogle Scholar
  21. 21.
    Vaidyanathan S, Barnes M, Williamson P, Hopkinson P, Donnan PT, Lipworth B. Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids: a randomized trial. Ann Intern Med. 2011;154(5):293–302.CrossRefGoogle Scholar
  22. 22.
    Head K, Chong LY, Hopkins C, Philpott C, Burton MJ, Schilder AG. Short-course oral steroids alone for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011991.PubMedGoogle Scholar
  23. 23.
    Hong CJ, Tsang AC, Quinn JG, Bonaparte JP, Stevens A, Kilty SJ. Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review. Syst Rev. 2015;4:166.CrossRefGoogle Scholar
  24. 24.
    Chang TW, Shiung YY. Anti-IgE as a mast cell-stabilizing therapeutic agent. J Allergy Clin Immunol. 2006;117(6):1203–12; quiz 13CrossRefGoogle Scholar
  25. 25.
    Para AJ, Clayton E, Peters AT. Management of rhinosinusitis: an evidence based approach. Curr Opin Allergy Clin Immunol. 2016;16(4):383–9.CrossRefGoogle Scholar
  26. 26.
    Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48(3):318–24.PubMedGoogle Scholar
  27. 27.
    Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133–41.CrossRefGoogle Scholar
  28. 28.
    Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–95, e1–8CrossRefGoogle Scholar
  29. 29.
    Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50.CrossRefGoogle Scholar
  30. 30.
    Akdis CA, Bachert C, Cingi C, Dykewicz MS, Hellings PW, Naclerio RM, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European academy of allergy and clinical immunology and the American academy of allergy, asthma & immunology. J Allergy Clin Immunol. 2013;131(6):1479–90.CrossRefGoogle Scholar
  31. 31.
    Bachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge P, Liu S, et al. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol. 2010;126(5):962–8, 8.e1–6CrossRefGoogle Scholar
  32. 32.
    Bachert C, van Steen K, Zhang N, Holtappels G, Cattaert T, Maus B, et al. Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma. J Allergy Clin Immunol. 2012;130(2):376–81.e8.CrossRefGoogle Scholar
  33. 33.
    Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–79.CrossRefGoogle Scholar
  34. 34.
    Rudmik L, Soler ZM, Hopkins C, Schlosser RJ, Peters A, White AA, et al. Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Rhinology. 2016;54(2):117–28.CrossRefGoogle Scholar
  35. 35.
    Sohal M, Tessema B, Brown SM. Medical management of frontal sinusitis. Otolaryngol Clin N Am. 2016;49(4):927–34.CrossRefGoogle Scholar
  36. 36.
    Santarelli GD, Han JK. Evaluation of the PROPEL(R) mini sinus implant for the treatment of frontal sinus disease. Expert Opin Drug Deliv. 2016;13(12):1789–93.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Kristine A. Smith
    • 1
  • Jeremiah A. Alt
    • 2
  • Richard R. Orlandi
    • 2
  1. 1.Division of Otolaryngology – Head and Neck Surgery, Department of SurgeryUniversity of CalgaryCalgaryUSA
  2. 2.Division of Otolaryngology – Head and Neck SurgeryUniversity of Utah School of MedicineSalt Lake CityUSA

Personalised recommendations